ReviewCell stem cell2026
Human pluripotent stem cell-derived innate and adaptive immune cells for cancer immunotherapy.
Review in Cell stem cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Induced pluripotent stem cell-derived natural killer cells: poised for the clinic as an off-the-shelf allogeneic cell therapy.Translational cancer research · 2026Article
- BCR-ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBPβ.MedComm · 2026Article
- Human iPSC-derived and conventional cancer models in precision oncology: advancing patient-specific therapies from bench to bedside.Journal of experimental & clinical cancer research : CR · 2026Review
- Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases.Precision clinical medicine · 2026Review
- From iPSC to manufactured iNK cells using CombiCult® screening platform.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Allogeneic cell-based therapies hold great promise for cancer immunotherapy but face challenges like scalability, immune rejection, graft-versus-host disease, and toxicities. Human pluripotent stem cells (hPSCs), including embryonic and induced pluripotent stem cells (iPSCs), offer a scalable and adaptable platform to address these limitations. hPSCs provide an inexhaustible source of immune cells that can be genetically modified at the single-cell level to enhance anti-tumor activity and reduce immunogenicity. Recent advancements in generating iPSC-derived natural killer (NK) cells, T cells, and macrophages are opening the door to safer and more effective immunotherapies. This review examines the progress, challenges, and future directions in utilizing hPSC-derived immune cells to enhance cancer treatment and overcome barriers in allogeneic therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.